Lumbar Spinal Stenosis
Conditions
Keywords
Back pain, Pain, Spinal Diseases, Spinal Stenosis, Lumbar Vertebrae, Spinal Canal
Brief summary
The purpose of this investigation is to evaluate the safety and effectiveness of the FLEXUS™ Interspinous Spacer as compared to the XSTOP® Spacer for the treatment of patients who are suffering from lumbar spinal stenosis at one or two contiguous levels.
Interventions
Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
Treatment of lumbar spinal stenosis with the XSTOP® Spacer
Sponsors
Study design
Eligibility
Inclusion criteria
* Lumbar spinal stenosis as defined by leg, buttock or groin pain, with or without back pain, that relieves during flexion, with radiographic confirmation of spinal stenosis by CT or MRI scans at one or two contiguous levels between L1 and S1. If back pain is also present, it must be partially relieved during flexion * Narrowing of the spinal canal, nerve root canal or intervertebral foramen at one or two levels * Able to sit for 50 minutes without pain * Able to walk 50 feet or more * Age 50 years or over * Has completed at least 6 months of conservative treatment * Has a Zurich Claudication Questionnaire (ZCQ) score of ≥ 1.5 for Physical Function (PF) and ≥ 1.5 for Symptom Severity (SS) * Other as specified in the approved protocol
Exclusion criteria
* Cannot sit for 50 minutes without pain * Cannot walk for more than 50 feet * Unremitting pain in any spinal position * Axial back pain only without leg, buttock, or groin pain * Fixed motor deficit * Cauda equine syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retension or incontinence) dysfunction * Severe symptomatic lumbar spinal stenosis at more than two levels * Significant instability of the lumbar spine * Has had any surgery of the lumbar spine * Morbid obesity defined as a body mass index \>40 or a weight more than 100 lbs over ideal body weight * Active systemic disease such as AIDS, HIV, Hepatitis, etc. * Active systemic or local infection * Angina, active rheumatoid arthritis, advanced diabetes or any other systemic disease that would affect the subject's welfare or outcome of the study * Osteoporosis, defined as DEXA bone density measured T-score \< -2.5 * Spinal metastasis to the vertebrae * Known allergy to device materials titanium, tantalum, or polyetheretherketone (PEEK) polymer * Other as specified in approved protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Less Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Score | 24 months | Change in the Zurich Claudication Questionnaire (ZCQ) score at 24 months compared with the score at baseline as follows: * Change of \>0.5 points in Physical Function on a scale of 1-4 points (lower values are considered a better outcome) * Change of \>0.5 points in Symptom Severity on a scale of 1-5 points (lower values are considered a better outcome) * Satisfaction of \<2.5 points on a scale of 1-4 points (lower values are considered a better outcome) The Zurich Claudication Questionnaire is a three part form that quantifies severity of symptoms, physical function characteristics, and patient's satisfaction after treatment. |
| Number of Participants With a Successful Neurologic Status | 24 months | Neurological status is based on four types of measurement parameters: motor, sensory, reflexes, and special assessments. Each parameter will be coded as follows: Motor 0 Total Paralysis 1. Palpable or Visible Contraction 2. Active Movement, Gravity Eliminated 3. Active Movement, Against Gravity 4. Active Movement, Against Some Resistance 5. Active Movement, Against Full Resistance Sensory 0 Absent 1. Impaired 2. Normal Reflexes 0 Absent or Trace 1. Hyper-reflexic 2. Normal or hypo-reflexic Straight Leg Raise 0 0°-70° (abnormal) 1 \>70°-90° (normal) If all evaluations for the parameter are determined to be normal, then the parameter is given a normal status. If any evaluations for the parameter are abnormal, then the parameter is given an abnormal status. The overall neurological status will be considered a success if and only if all the four parameters are stable or improved. |
| Number of Participants With no Additional Surgery for Lumbar Spinal Stenosis at the Spinal Level That Was Treated | 24 months | Measures the number of participants who did not have another surgery for treatment of lumbar spinal stenosis at the same spinal level that was originally treated. Data, including adverse events, were monitored, evaluated and assessed for evidence of additional surgical treatment at the spinal level that was originally treated. |
| Number of Participants With an Absence of Implant-related Complications | 24 months | Absence of implant-related complications, including device dislodgement, defined as: * Failure of implant material (e.g. fracture); * Implant migration outside of the interspinous space (posteriorly beyond the posterior margin of the spinous processes, anteriorly within the spinal canal, or laterally more than half of the implant width); or * Other complications that can be specifically associated with the implanted device. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Oswestry Disability Index (ODI) at 24 Months | 24 months | The Oswestry Disability Index (ODI) questionnaire contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel. Each topic is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. The subject chooses the statement which most closely resembles their situation. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. Scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability. |
| Change of Quality of Life | 24 months | Change in mental or physical composite score of the short form SF36 |
| Mean Visual Analog Scale (VAS) - Back Pain at 24 Months | 24 months | The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with no pain on the left border and as severe as it could be on the right border. The subject is instructed to make a mark along the line to represent the intensity of back pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale. |
| Mean Visual Analog Scale (VAS) - Right Leg Pain at 24 Months | 24 months | The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with no pain on the left border and as severe as it could be on the right border. The subject is instructed to make a mark along the line to represent the intensity of right leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale. |
| Mean Visual Analog Scale (VAS) - Left Leg Pain at 24 Months | 24 months | The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with no pain on the left border and as severe as it could be on the right border. The subject is instructed to make a mark along the line to represent the intensity of left leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| FLEXUS™ Interspinous Spacer FLEXUS(TM) Interspinous Spacer: Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer | 107 |
| X-STOP® Interspinous Spacer X-STOP® Interspinous Spacer: Treatment of lumbar spinal stenosis with the X-STOP® Spacer | 106 |
| No Treatment Not treated with FLEXUS or X-STOP | 2 |
| Total | 215 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 5 | 3 | 0 |
| Overall Study | No data | 29 | 22 | 2 |
Baseline characteristics
| Characteristic | Total | FLEXUS™ Interspinous Spacer | X-STOP® Interspinous Spacer | No Treatment |
|---|---|---|---|---|
| Age, Continuous | 67.8 years STANDARD_DEVIATION 8.87 | 68.2 years STANDARD_DEVIATION 8.93 | 67.3 years STANDARD_DEVIATION 8.88 | 71.5 years STANDARD_DEVIATION 4.95 |
| Height (inches) | 67.1 inches STANDARD_DEVIATION 3.84 | 67.0 inches STANDARD_DEVIATION 3.62 | 67.2 inches STANDARD_DEVIATION 3.94 | 66.0 inches STANDARD_DEVIATION 11.31 |
| Race/Ethnicity, Customized Race Asian | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Black | 10 Participants | 7 Participants | 3 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Caucasian | 202 Participants | 98 Participants | 102 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Hispanic | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Other | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Sex: Female, Male Female | 101 Participants | 54 Participants | 46 Participants | 1 Participants |
| Sex: Female, Male Male | 114 Participants | 53 Participants | 60 Participants | 1 Participants |
| Weight (lbs) | 187.5 lbs STANDARD_DEVIATION 36.45 | 181.8 lbs STANDARD_DEVIATION 33.87 | 193.2 lbs STANDARD_DEVIATION 37.75 | 195.0 lbs STANDARD_DEVIATION 77.78 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 5 / 107 | 3 / 106 | 0 / 2 |
| other Total, other adverse events | 77 / 107 | 72 / 106 | 2 / 2 |
| serious Total, serious adverse events | 41 / 107 | 28 / 106 | 0 / 2 |
Outcome results
Number of Participants With an Absence of Implant-related Complications
Absence of implant-related complications, including device dislodgement, defined as: * Failure of implant material (e.g. fracture); * Implant migration outside of the interspinous space (posteriorly beyond the posterior margin of the spinous processes, anteriorly within the spinal canal, or laterally more than half of the implant width); or * Other complications that can be specifically associated with the implanted device.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed in the FLEXUS arm and X-STOP arm is the number of subjects who started the Study in the respective arms. No data was collected for the No Treatment arm.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| FLEXUS™ Interspinous Spacer | Number of Participants With an Absence of Implant-related Complications | 84 Participants |
| X-STOP® Interspinous Spacer | Number of Participants With an Absence of Implant-related Complications | 97 Participants |
| No Treatment | Number of Participants With an Absence of Implant-related Complications | 0 Participants |
Number of Participants With a Successful Neurologic Status
Neurological status is based on four types of measurement parameters: motor, sensory, reflexes, and special assessments. Each parameter will be coded as follows: Motor 0 Total Paralysis 1. Palpable or Visible Contraction 2. Active Movement, Gravity Eliminated 3. Active Movement, Against Gravity 4. Active Movement, Against Some Resistance 5. Active Movement, Against Full Resistance Sensory 0 Absent 1. Impaired 2. Normal Reflexes 0 Absent or Trace 1. Hyper-reflexic 2. Normal or hypo-reflexic Straight Leg Raise 0 0°-70° (abnormal) 1 \>70°-90° (normal) If all evaluations for the parameter are determined to be normal, then the parameter is given a normal status. If any evaluations for the parameter are abnormal, then the parameter is given an abnormal status. The overall neurological status will be considered a success if and only if all the four parameters are stable or improved.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed is not consistent with numbers in the Participant Flow module. The discrepancy is due to two less subjects having neurologic status data at 24 months in the FLEXUS arm and one less subject with neurologic status data at 24 months in the X-STOP arm. No data was collected for the No Treatment arm.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| FLEXUS™ Interspinous Spacer | Number of Participants With a Successful Neurologic Status | 60 Participants |
| X-STOP® Interspinous Spacer | Number of Participants With a Successful Neurologic Status | 69 Participants |
| No Treatment | Number of Participants With a Successful Neurologic Status | 0 Participants |
Number of Participants With Less Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Score
Change in the Zurich Claudication Questionnaire (ZCQ) score at 24 months compared with the score at baseline as follows: * Change of \>0.5 points in Physical Function on a scale of 1-4 points (lower values are considered a better outcome) * Change of \>0.5 points in Symptom Severity on a scale of 1-5 points (lower values are considered a better outcome) * Satisfaction of \<2.5 points on a scale of 1-4 points (lower values are considered a better outcome) The Zurich Claudication Questionnaire is a three part form that quantifies severity of symptoms, physical function characteristics, and patient's satisfaction after treatment.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed is not consistent with numbers provided in the Participant Flow module. The discrepancy in the numbers is due to an additional subject having ZCQ data at 24 months in the FLEXUS arm and one less subject with ZCQ data at 24 months in the X-STOP group. No data was collected for the No Treatment arm.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| FLEXUS™ Interspinous Spacer | Number of Participants With Less Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Score | 42 Participants |
| X-STOP® Interspinous Spacer | Number of Participants With Less Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Score | 50 Participants |
| No Treatment | Number of Participants With Less Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Score | 0 Participants |
Number of Participants With no Additional Surgery for Lumbar Spinal Stenosis at the Spinal Level That Was Treated
Measures the number of participants who did not have another surgery for treatment of lumbar spinal stenosis at the same spinal level that was originally treated. Data, including adverse events, were monitored, evaluated and assessed for evidence of additional surgical treatment at the spinal level that was originally treated.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed in the FLEXUS arm and X-STOP arm is the number of subjects who started the Study in the respective arm. No data was collected for the No Treatment arm.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| FLEXUS™ Interspinous Spacer | Number of Participants With no Additional Surgery for Lumbar Spinal Stenosis at the Spinal Level That Was Treated | 90 Participants |
| X-STOP® Interspinous Spacer | Number of Participants With no Additional Surgery for Lumbar Spinal Stenosis at the Spinal Level That Was Treated | 99 Participants |
| No Treatment | Number of Participants With no Additional Surgery for Lumbar Spinal Stenosis at the Spinal Level That Was Treated | 0 Participants |
Change of Quality of Life
Change in mental or physical composite score of the short form SF36
Time frame: 24 months
Population: The short form SF36 was administered to study patients; however, we do not have the proprietary scoring system. Hence the scores could not be calculated.
Mean Oswestry Disability Index (ODI) at 24 Months
The Oswestry Disability Index (ODI) questionnaire contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel. Each topic is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. The subject chooses the statement which most closely resembles their situation. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. Scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed is not consistent with numbers in the Participant Flow module. The discrepancy is due to ten less subjects having ODI data at 24 months in the FLEXUS arm and four less subject with ODI data at 24 months in the X-STOP arm. No data was collected for the No Treatment arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FLEXUS™ Interspinous Spacer | Mean Oswestry Disability Index (ODI) at 24 Months | 19.2 score | Standard Deviation 17.97 |
| X-STOP® Interspinous Spacer | Mean Oswestry Disability Index (ODI) at 24 Months | 17.4 score | Standard Deviation 14.15 |
Mean Visual Analog Scale (VAS) - Back Pain at 24 Months
The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with no pain on the left border and as severe as it could be on the right border. The subject is instructed to make a mark along the line to represent the intensity of back pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed is not consistent with numbers in the Participant Flow module. The discrepancy is due to ten less subjects having ODI data at 24 months in the FLEXUS arm and four less subject with ODI data at 24 months in the X-STOP arm. No data was collected for the No Treatment arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FLEXUS™ Interspinous Spacer | Mean Visual Analog Scale (VAS) - Back Pain at 24 Months | 20.2 millimeters | Standard Deviation 27.77 |
| X-STOP® Interspinous Spacer | Mean Visual Analog Scale (VAS) - Back Pain at 24 Months | 18.8 millimeters | Standard Deviation 27.36 |
Mean Visual Analog Scale (VAS) - Left Leg Pain at 24 Months
The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with no pain on the left border and as severe as it could be on the right border. The subject is instructed to make a mark along the line to represent the intensity of left leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed is not consistent with numbers in the Participant Flow module. The discrepancy is due to eleven less subjects having VAS data at 24 months in the FLEXUS arm and four less subject with VAS data at 24 months in the X-STOP arm. No data was collected for the No Treatment arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FLEXUS™ Interspinous Spacer | Mean Visual Analog Scale (VAS) - Left Leg Pain at 24 Months | 13.2 millimeters | Standard Deviation 27.43 |
| X-STOP® Interspinous Spacer | Mean Visual Analog Scale (VAS) - Left Leg Pain at 24 Months | 10.7 millimeters | Standard Deviation 20.11 |
Mean Visual Analog Scale (VAS) - Right Leg Pain at 24 Months
The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with no pain on the left border and as severe as it could be on the right border. The subject is instructed to make a mark along the line to represent the intensity of right leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.
Time frame: 24 months
Population: The Overall Number of Participants Analyzed is not consistent with numbers in the Participant Flow module. The discrepancy is due to eleven less subjects having VAS data at 24 months in the FLEXUS arm and four less subject with VAS data at 24 months in the X-STOP arm. No data was collected for the No Treatment arm.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FLEXUS™ Interspinous Spacer | Mean Visual Analog Scale (VAS) - Right Leg Pain at 24 Months | 16.2 millimeters | Standard Deviation 26.72 |
| X-STOP® Interspinous Spacer | Mean Visual Analog Scale (VAS) - Right Leg Pain at 24 Months | 9.2 millimeters | Standard Deviation 15.77 |